GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Operating Margin %

OCGN (Ocugen) Operating Margin % : -1,811.52% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Ocugen's Operating Income for the three months ended in Dec. 2024 was $-13.84 Mil. Ocugen's Revenue for the three months ended in Dec. 2024 was $0.76 Mil. Therefore, Ocugen's Operating Margin % for the quarter that ended in Dec. 2024 was -1,811.52%.

The historical rank and industry rank for Ocugen's Operating Margin % or its related term are showing as below:

OCGN' s Operating Margin % Range Over the Past 10 Years
Min: -33220.93   Med: -2465.19   Max: -1085.67
Current: -1350.36


OCGN's Operating Margin % is ranked worse than
78.02% of 992 companies
in the Biotechnology industry
Industry Median: -127.94 vs OCGN: -1350.36

Ocugen's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Ocugen's Operating Income for the three months ended in Dec. 2024 was $-13.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-54.76 Mil.


Ocugen Operating Margin % Historical Data

The historical data trend for Ocugen's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Operating Margin % Chart

Ocugen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33,220.93 - -3,580.02 -1,085.67 -1,350.36

Ocugen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -817.96 -1,204.73 -1,353.99 -1,166.55 -1,811.52

Competitive Comparison of Ocugen's Operating Margin %

For the Biotechnology subindustry, Ocugen's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ocugen's Operating Margin % falls into.


;
;

Ocugen Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ocugen's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-54.757 / 4.055
=-1,350.36 %

Ocugen's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=-13.84 / 0.764
=-1,811.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocugen  (NAS:OCGN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ocugen Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ocugen's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen Business Description

Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Executives
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355